Cancer Chemotherapy and Pharmacology
Overview
Cancer Chemotherapy and Pharmacology is a peer-reviewed journal that focuses on the latest advancements in the field of cancer treatment and pharmacology. It publishes original research articles, reviews, and clinical studies, covering various aspects of chemotherapy, drug development, pharmacokinetics, and pharmacodynamics. The journal aims to provide valuable insights into the efficacy, safety, and mechanisms of anticancer drugs, fostering the development of novel therapeutic strategies for cancer patients.
Details
Details
Metrics
Metrics
h-index / Ranks: 2180
122
SJR / Ranks: 4687
869
CiteScore / Ranks: 3626
6.20
JIF / Ranks: 3481
3.0
Recent Articles
21.
Oliveira-Silva J, Oliveira L, Chiminazo C, Fonseca R, Souza C, Aissa A, et al.
Cancer Chemother Pharmacol
. 2025 Jan;
95(1):22.
PMID: 39821335
Purpose: Histone deacetylase 6 (HDAC6) plays a critical role in tumorigenesis and tumor progression, contributing to proliferation, chemoresistance, and cell motility by regulating microtubule architecture. Despite its upregulation in melanoma...
22.
Meertens M, Giraud E, Hassan E, Zielhuis S, Snels T, Desar I, et al.
Cancer Chemother Pharmacol
. 2025 Jan;
95(1):25.
PMID: 39820703
Purpose: After initial approval of lenvatinib for radioiodine-refractory differentiated thyroid cancer (DTC), it has also shown promising outcomes in among others metastatic renal cell carcinoma (mRCC). Given that trial populations...
23.
Zheng K, Jin G, Cao R, Gao Y, Xu J, Chai R, et al.
Cancer Chemother Pharmacol
. 2025 Jan;
95(1):21.
PMID: 39792198
Purpose: Ovarian clear cell carcinoma is a highly malignant gynecological tumor characterized by a high rate of chemotherapy resistance and poor prognosis. The PI3K/AKT/mTOR pathway is well-known to be closely...
24.
Cheng C, Chuang W, Lin C, Li C, Chang H, Wu W, et al.
Cancer Chemother Pharmacol
. 2025 Jan;
95(1):20.
PMID: 39792181
Objective: Based on our previous research, which demonstrated that elevated plasma endoglin (ENG) levels in lung cancer patients were associated with a better prognosis, increased sensitivity to pemetrexed, and enhanced...
25.
Liu D, Li Q, Yan S, Zhang X, Li W, Wang F, et al.
Cancer Chemother Pharmacol
. 2025 Jan;
95(1):19.
PMID: 39776242
Purpose: PLB1004, developed by Beijing Avistone Biotechnology Co., Ltd., is a safe, highly selective, and efficient irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) employed in treating non-small-cell-lung-cancer (NSCLC)....
26.
Collins K, Yin D, Pithavala Y, Mittapalli R
Cancer Chemother Pharmacol
. 2025 Jan;
95(1):17.
PMID: 39754626
As development of new oncology small molecule therapies is focused mainly on molecularly targeted agents, the dose selection paradigm has shifted from the maximum tolerated dose (MTD)-based approach traditionally utilized...
27.
Kumar N, Mangla M
Cancer Chemother Pharmacol
. 2025 Jan;
95(1):18.
PMID: 39754614
Introduction: Gynecological cancers, such as ovarian, cervical, and endometrial malignancies, are notoriously challenging due to their intricate biology and the critical need for precise diagnostic and therapeutic approaches. In recent...
28.
Vilquin P, Medard Y, Thomas F, Goldwirt L, Teixeira L, Mourah S, et al.
Cancer Chemother Pharmacol
. 2025 Jan;
95(1):16.
PMID: 39745516
The enzyme dihydropyrimidine dehydrogenase (DPD) is the primary catabolic pathway of fluoropyrimidines including 5 fluorouracil (5FU) and capecitabine. Cases of lethal toxicity have been reported in cancer patients with complete...
29.
Yang S, Liu S, Dai Z
Cancer Chemother Pharmacol
. 2024 Dec;
95(1):15.
PMID: 39739023
Background: Polygala tenuifolia and its active components have been revealed to possess anti-tumor activities. However, the role of Tenuigenin (TEN), a bioactive ingredient from Polygala tenuifolia, in tumors such as...
30.
Sato M, Araki T, Yashima H, Ishikawa Y, Morita J, Maeda Y, et al.
Cancer Chemother Pharmacol
. 2024 Dec;
95(1):14.
PMID: 39724407
Purpose: The blood concentrations of some tyrosine kinase inhibitors are known to decrease with long-term administration. We evaluated the variability in the serum concentrations of sunitinib and its metabolites in...